Risk of Malignancy According to the Sub-classification of Atypia of Undetermined Significance and Suspicious Follicular Neoplasm Categories in Thyroid Core Needle Biopsies

被引:0
作者
Sae Rom Chung
Jung Hwan Baek
Jeong Hyun Lee
Yu-Mi Lee
Tae-Yon Sung
Ki-Wook Chung
Suck Joon Hong
Min Ji Jeon
Tae Yong Kim
Young Kee Shong
Won Bae Kim
Won Gu Kim
Dong Eun Song
机构
[1] University of Ulsan College of Medicine,Departments of Radiology Asan Medical Center
[2] University of Ulsan College of Medicine,Departments of Surgery Asan Medical Center
[3] University of Ulsan College of Medicine,Departments of Internal Medicine Asan Medical Center
[4] University of Ulsan College of Medicine,Departments of Pathology, Asan Medical Center
来源
Endocrine Pathology | 2019年 / 30卷
关键词
Thyroid; Atypia of undetermined significance; Follicular neoplasm; Core needle biopsy; Risk of malignancy; Sub-category;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study was to evaluate the risk of malignancy (ROM) associated with atypia of undetermined significance (AUS) and suspicious follicular neoplasm (SFN) core needle biopsy (CNB) categories after further sub-classification. Data from 2267 thyroid nodules evaluated by ultrasound-guided CNB, from January to December 2015, were retrospectively reviewed. AUS nodules (n = 556) were sub-classified as follows: (1) architectural atypia (AUS-A; n = 369, 66.4%), (2) cytologic atypia (AUS-C; n = 35, 6.3%), (3) cytologic/architectural atypia (AUS-C/A; n = 85, 15.3%), or (4) oncocytic atypia (AUS-O; n = 67, 12.1%). SFN nodules (n = 172) were sub-classified as follows: (1) architectural atypia only (SFN-A; n = 110, 64%), (2) cytologic/architectural atypia (SFN-C/A; n = 24, 14%), or (3) oncocytic atypia (SFN-O; n = 38, 22%). Diagnostic surgery was performed in 162 (30.2%) AUS cases and 105 (61%) SFN cases. The ROM of each sub-category was evaluated. The overall ROM was 15.3–52.5% in AUS nodules and 35.5–58.1% in SFN nodules. The ROM was higher in the AUS-C (22.9–88.9%) and AUS-C/A (32.9–90.3%) groups than AUS-A (11.9–40%) and AUS-O (7.5–41.7%). In the SFN category, ROM in the SFN-C/A group was also higher than SFN-A or SFN-O (37.5–75%, 40–57.9%, and 21.1–47.1%, respectively). Our study shows that the ROM was higher in AUS or SFN sub-categories with cytologic atypia than those without cytologic atypia. Because of the heterogeneous nature of AUS and SFN categories, sub-classification may be a more effective approach for risk stratification, allowing optimal management of patients with thyroid nodules.
引用
收藏
页码:146 / 154
页数:8
相关论文
共 40 条
  • [31] The presence of papillary features in thyroid nodules diagnosed as atypia of undetermined significance or follicular lesion of undetermined significance increases cancer risk and should influence treatment
    Oosthuizen, Jean L.
    Walker, Blair
    Todorovic, Emilija
    Masoudi, Hamid
    Wiseman, Sam M.
    AMERICAN JOURNAL OF SURGERY, 2018, 215 (05) : 819 - 823
  • [32] BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined Significance
    Adeniran, Adebowale J.
    Hui, Pei
    Chhieng, David C.
    Prasad, Manju L.
    Schofield, Kevin
    Theoharis, Constantine
    ACTA CYTOLOGICA, 2011, 55 (06) : 570 - 575
  • [33] Clinical Parameter for Deciding the BRAFV600E Mutation Test in Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Thyroid Nodules: US Features According to TIRADS
    Rho, Miribi
    Kim, Eun-Kyung
    Moon, Hee Jung
    Yoon, Jung Hyun
    Park, Vivian Y.
    Han, Kyunghwa
    Kwak, Jin Young
    ULTRASOUND QUARTERLY, 2017, 33 (04) : 284 - 288
  • [34] The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results
    Hyeon, Jiyeon
    Ahn, Soomin
    Shin, Jung Hee
    Oh, Young Lyun
    CANCER CYTOPATHOLOGY, 2014, 122 (05) : 368 - 376
  • [35] Distribution and malignancy risk of six categories of the pathology reporting system for thyroid core-needle biopsy in 1,216 consecutive thyroid nodules
    Son, Hye Min
    Kim, Ji-hoon
    Kim, Soo Chin
    Yoo, Roh-Eul
    Bae, Jeong Mo
    Seo, Hyobin
    Na, Dong Gyu
    ULTRASONOGRAPHY, 2020, 39 (02) : 159 - 165
  • [36] Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology
    Torres, Jaylou M. Velez
    Curnow, Porshya M.
    Tjendra, Youley
    Jorda, Merce
    Fernandez, Carmen Gomez
    Buitrago, Monica Garcia
    Zuo, Yiqin
    Cordero, Roberto Ruiz
    CANCER CYTOPATHOLOGY, 2024, 132 (08) : 491 - 498
  • [37] Impact of Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Features on Adequacy Criteria and Risk of Malignancy of Thyroid Fine-Needle Aspiration
    Renshaw, Andrew A.
    Gould, Edwin W.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 148 (03) : 259 - 263
  • [38] Subclassification of Atypical Cells of Undetermined Significance in Direct Smears of Fine-Needle Aspirations of the Thyroid Distinct Patterns and Associated Risk of Malignancy
    Renshaw, Andrew A.
    CANCER CYTOPATHOLOGY, 2011, 119 (05) : 322 - 327
  • [39] Non-invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) Lowers the Risk of Malignancy in the Bethesda System for Reporting Thyroid Cytopathology Diagnostic Categories
    Al-Maghrabi, Hatim
    Tashkandi, Mohamed
    Khayyat, Waleed
    Alghamdi, Amer
    Alsalmi, Mohammed
    Alzahrani, Alhussain
    Al-Hakami, Hadi
    Alqarni, Mohammed
    SAUDI JOURNAL OF MEDICINE & MEDICAL SCIENCES, 2022, 10 (02) : 105 - 110
  • [40] Subclassifying "Atypia of Undetermined Significance (AUS)" Category in the 2023 Bethesda System for Thyroid Cytopathology: Analyzing K-TIRADS, BRAF V600E Mutation, and Risk of Malignancy
    Bang, Heejin
    Cho, Chulshin
    Kim, Mi Young
    Hyeon, Jiyeon
    Lee, Seung Eun
    ENDOCRINE PATHOLOGY, 2025, 36 (01)